Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $156000.0.

  • Phathom Pharmaceuticals' Depreciation & Amortization (CF) fell 1832.46% to $156000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $698000.0, marking a year-over-year decrease of 1130.88%. This contributed to the annual value of $795000.0 for FY2024, which is 3826.09% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $156000.0 for Q3 2025, which was down 1832.46% from $172000.0 recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $214000.0 for Q1 2024, and its period low was $121000.0 during Q3 2023.
  • Its 4-year average for Depreciation & Amortization (CF) is $166333.3, with a median of $172000.0 in 2025.
  • In the last 5 years, Phathom Pharmaceuticals' Depreciation & Amortization (CF) crashed by 3085.71% in 2023 and then skyrocketed by 6016.26% in 2024.
  • Over the past 4 years, Phathom Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $168000.0 in 2022, then rose by 10.12% to $185000.0 in 2023, then grew by 4.32% to $193000.0 in 2024, then dropped by 19.17% to $156000.0 in 2025.
  • Its last three reported values are $156000.0 in Q3 2025, $172000.0 for Q2 2025, and $177000.0 during Q1 2025.